Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: Results of a markov model analysis

Fajutrao, Liberty; Paulsson, Björn; Liu, Sherry; Locklear, Julie

doi:10.1016/j.clinthera.2009.06.009

Cited by 18 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the modeling studies in our review had a clear definition of the decision problem, model objectives, and scope. Different modeling approaches were used to address the study question, including one decision tree model , eight cohort‐based Markov models , two DES studies , two publications using the same mathematical model , and two studies that failed to explicitly state their approach or structure . All studies except Klok et al.…”

Section: Resultsmentioning

confidence: 99%

Economic evaluations in bipolar disorder: a systematic review and critical appraisal

et al. 2014

View full text Add to dashboard Cite

The cost-effectiveness of different treatment strategies varied between settings, and transferability of these results across settings remains questionable. Although additional research using a longer time horizon is required to validate the findings for trial-based economic evaluations, discrete event simulation appears to be the most natural and plausible technique for modeling the cost-effectiveness of alternative BD treatment strategies.

show abstract

Section: Resultsmentioning

confidence: 99%

Economic evaluations in bipolar disorder: a systematic review and critical appraisal

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Since QUE has synergistic antitumor effects with TMZ, combined application may also help reduce treatment dose of TMZ and its related toxic effect. Moreover, the reduced cost of QUE compared to TMZ [38, 39] can be a considerable benefit factor to the patient in chemotherapy of glioma.…”

Section: Discussionmentioning

confidence: 99%

Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma

et al. 2017

View full text Add to dashboard Cite

As a major contributor of chemotherapy resistance and malignant recurrence, glioma stem cells (GSCs) have been proposed as a target for the treatment of gliomas. To evaluate the therapeutic potential of quetiapine (QUE), an atypical antipsychotic, for the treatment of malignant glioma, we established mouse models with GSCs-initiated orthotopic xenograft gliomas and subcutaneous xenograft tumors, using GSCs purified from glioblastoma cell line GL261. We investigated antitumor effects of QUE on xenograft gliomas and its underlying mechanisms on GSCs. Our data demonstrated that (i) QUE monotherapy can effectively suppress GSCs-initiated tumor growth; (ii) QUE has synergistic effects with temozolomide (TMZ) on glioma suppression, and importantly, QUE can effectively suppress TMZ-resistant (or -escaped) tumors generated from GSCs; (iii) mechanistically, the anti-glioma effect of QUE was due to its actions of promoting the differentiation of GSCs into oligodendrocyte (OL)-like cells and its inhibitory effect on the Wnt/β-catenin signaling pathway. Together, our findings suggest an effective approach for anti-gliomagenic treatment via targeting OL-oriented differentiation of GSCs. This also opens a door for repurposing QUE, an FDA approved drug, for the treatment of malignant glioma.

show abstract

“…Even though cost-effectiveness of different SGAs in the treatment of patients experiencing a manic episode associated with bipolar I disorder has been studied in numerous analyses and in different contexts [21–26], only a few studies [27, 28] have explored the role of these drugs in patients with mixed episodes.…”

Section: Introductionmentioning

confidence: 99%

Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context

Caresano

Sciascio²,

Fagiolini

et al. 2014

Adv Ther

View full text Add to dashboard Cite

IntroductionBipolar disorder is a chronic disease characterized by periods of mania or hypomania, depression, or a combination of both (mixed state). Because bipolar disorder is one of the leading causes of disability, it represents an important economic burden on society. Asenapine (ASE) is a new second-generation antipsychotic developed and approved for the treatment of manic or mixed episodes associated with bipolar disorder. The objective of the present study was to assess the cost-effectiveness of ASE compared to olanzapine (OLA) in the treatment of patients experiencing mixed episodes associated with bipolar I disorder in the context of the Italian National Health Service (NHS).MethodsA pharmacoeconomic model was developed to simulate the management of Italian bipolar I patients with mixed episodes over a 5-year time horizon by combining clinical parameters with resource utilization. An expert panel of Italian psychiatrists and health economists was responsible for adapting a UK model to the Italian context. The primary outcome measure of the economic evaluation was the incremental cost effectiveness ratio, where effectiveness is measured in terms of quality adjusted life-years gained. Scenario analyses, sensitivity analyses, and a probabilistic sensitivity analysis were performed to test the robustness of the model.ResultsThis pharmacoeconomic model showed that ASE resulted to be dominant over OLA; in fact, ASE was associated with lower direct costs (derived largely by the savings from hospitalizations avoided) and also generated a better quality of life. Results were robust to changes in key parameters; both scenario analyses and sensitivity analyses demonstrated model reliability.ConclusionsResults from this study suggest that the management of bipolar I patients with mixed episodes using ASE as alternative to OLA can lead to cost saving for the Italian NHS and improve patients quality of life.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-014-0139-3) contains supplementary material, which is available to authorized users.

show abstract

Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: Results of a markov model analysis

Cited by 18 publications

References 20 publications

Economic evaluations in bipolar disorder: a systematic review and critical appraisal

Economic evaluations in bipolar disorder: a systematic review and critical appraisal

Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma

Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context

Contact Info

Product

Resources

About